PHILADELPHIA, Aug. 21 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:
GSK) today announced that, beginning in February 2009, the company will
proactively report educational and charitable grants provided to US
health-related organizations. The report will be updated on a quarterly
basis and will include grants provided to various organizations including
hospitals, teaching institutions, managed care organizations, professional
associations, patient advocacy groups, and continuing medical education
companies.
GSK provides grants for programs and organizations that foster
increased understanding of scientific, clinical, and healthcare issues, and
contribute to the enhancement of patient care.
"GSK sponsors a range of third-party independent educational programs
to increase awareness and knowledge about health-related issues," said
Chris Viehbacher, President, North American Pharmaceuticals,
GlaxoSmithKline. "By publishing information about our grants, we
transparently identify the support we offer for independent and quality
education to improve the delivery of health care for patients."
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer. For company information, visit GlaxoSmithKline on the World Wide
Web at http://us.gsk.com.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995, GSK cautions investors that any
forward-looking statements or projections made by GSK, including those made
in this announcement, are subject to risks and uncertainties that may cause
actual results to differ materially from those projected. Factors that may
affect GSK's operations are described under 'Risk Factors' in the 'Business
Review' in the company's Annual Report on Form 20-F for 2007.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
SOURCE GlaxoSmithKline
 back to top
Related links:
http://www.gsk.com
http://us.gsk.com
http://www.prnewswire.com/comp/801350.html /
CONTACT:
US Media: Nancy Pekarek, +1-919-483-2839, or
Mary Anne Rhyne, +1-919-483-2839, or Sarah Alspach,
+1-215-751-7709, or US Analyst-Investor: Frank Murdolo,
+1-215-751-7002, or Tom Curry, 1-215-751-5419, all of
GlaxoSmithKline
|
